Status:
COMPLETED
Glimepiride Induced Insulin Secretion Will be Inhibited by Hypoglycemia
Lead Sponsor:
Vanderbilt University
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
30-60 years
Phase:
NA
Brief Summary
This study will look at two FDA approved medications that improve how the pancreas works in patients with Type 2 Diabetes. In order to understand how these medications work in patients with diabetes w...
Detailed Description
In patients with type 2 diabetes, sulfonylurea drugs are a mainstay for effective glucose control. These agents produce their hypoglycemic effects via stimulation of endogenous insulin secretion. Over...
Eligibility Criteria
Inclusion
- Healthy male and female subjects aged 30-60
- Body Mass Index 21-30 kg/m2
- All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities
- EKG treadmill stress test for volunteers over 40 years of age.
- Female volunteers of childbearing potential will undergo HCG pregnancy test.
Exclusion
- Prior or current history of poor health
- Abnormal results following screening tests
- Pregnancy
- History of allergy to sulfonylurea or related drugs
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00608179
Start Date
August 1 2002
End Date
December 1 2010
Last Update
December 11 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.